- The clinical trial imaging market has been growing rapidly, driven by the increasing use of advanced imaging technologies such as magnetic resonance imaging and positron emission tomography in drug development and clinical trials
- For instance, the use of MRI in neurology trials has helped researchers better understand the effects of treatments on brain conditions
- Imaging technologies are now essential for tracking disease progression and treatment responses, helping researchers monitor the effects of new therapies with higher precision
- For instance, in cardiovascular trials, CT scans are often used to assess heart function and arterial health in response to new drugs
- Real-time imaging solutions have become crucial in oncology trials, where accurate tumor assessment is needed to evaluate treatment efficacy, such as in the case of PET scans used in cancer research
- For instance, PET scans, are frequently used in studies such as the development of targeted therapies for lung cancer
- Collaboration between imaging companies and contract research organizations has improved service integration, enhancing workflow efficiency and reducing timelines in clinical trials. Companies such as Covance and Parexel have partnered with imaging firms to provide seamless trial management services that include imaging data collection and analysis
- The integration of artificial intelligence in imaging systems has elevated the accuracy of data analysis, with AI helping to automatically detect changes in scans, speeding up the assessment process and reducing human error. AI is particularly beneficial in clinical trials such as Alzheimer’s disease, where it helps identify early signs of neurodegeneration from MRI scans
